Ashlee Joseph
YOU?
Author Swipe
View article: Treatment and outcomes of progression of disease post–CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis
Treatment and outcomes of progression of disease post–CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis Open
The treatment patterns and clinical outcomes for patients experiencing progression of disease (POD) following CD19-directed chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) mantle cell lymphoma (MCL) are unde…
View article: 612 | FACTORS INFORMING OPTIMAL MANAGEMENT OF OLDER ADULTS WITH MANTLE CELL LYMPHOMA AMIDST A CHANGING THERAPEUTIC LANDSCAPE: LESSONS FROM A 25‐YEAR INSTITUTIONAL EXPERIENCE
612 | FACTORS INFORMING OPTIMAL MANAGEMENT OF OLDER ADULTS WITH MANTLE CELL LYMPHOMA AMIDST A CHANGING THERAPEUTIC LANDSCAPE: LESSONS FROM A 25‐YEAR INSTITUTIONAL EXPERIENCE Open
View article: Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a <i>TP53</i> mutation
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a <i>TP53</i> mutation Open
TP53-mutant mantle cell lymphoma (MCL) is associated with poor survival outcomes with standard chemoimmunotherapy. We conducted a multicenter, phase 2 study of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in untreated patients with M…
View article: <i>Erratum</i> to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
<i>Erratum</i> to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation Open
View article: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation Open
Chemoimmunotherapy followed by consolidative high-dose therapy with autologous stem cell rescue was a standard upfront treatment for fit patients with mantle cell lymphoma (MCL) in first remission; however, treatment paradigms are evolving…
View article: PHASE I STUDY OF BENDAMUSTINE, RITUXIMAB, IBRUTINIB, AND VENETOCLAX IN RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA
PHASE I STUDY OF BENDAMUSTINE, RITUXIMAB, IBRUTINIB, AND VENETOCLAX IN RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA Open
Introduction: Bendamustine (B) and rituximab (R) with ibrutinib (IBR) was well-tolerated and efficacious (Maddocks Blood 2015). Ibrutinib and venetoclax (VEN) were synergistic and active in relapsed, refractory (R/R) MCL (Tam NEJM 2018). V…
View article: Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma Open
PURPOSE To improve curability and limit long-term adverse effects for newly diagnosed early-stage (ES), unfavorable-risk Hodgkin lymphoma. METHODS In this multicenter study with four sequential cohorts, patients received four cycles of bre…